门诊治疗 COVID-19 的口服药物：疗效和价值。
Oral treatments for outpatient COVID-19: Effectiveness and value.
机构信息
Institute for Clinical and Economic Review, Boston, MA.
Kaiser Permanente Washington Health Research Institute, Seattle.
出版信息
J Manag Care Spec Pharm. 2022 Aug;28(8):903-909. doi: 10.18553/jmcp.2022.28.8.903.
Ms Beinfeld and Nahn and Drs Whittington, Mohammed, and Pearson report grants from Arnold Ventures, Kaiser Foundation Health Plan Inc., The Patrick and Catherine Weldon Donaghue Medical Research Foundation, Blue Cross Blue Shield of Massachusetts, and The Commonwealth Foundation, during the conduct of the study; and other from America's Health Insurance Plans, Anthem, AbbVie, Alnylam, AstraZeneca, Biogen, Blue Shield of CA, Cambia Health Services, CVS, Editas, Express Scripts, Genentech/Roche, GlaxoSmithKline, Harvard Pilgrim, Health Care Service Corporation, Health Partners, Johnson & Johnson (Janssen), Kaiser Permanente, LEO Pharma, Mallinckrodt, Merck, Novartis, National Pharmaceutical Council, Premera, Prime Therapeutics, Regeneron, Sanofi, United Healthcare, HealthFirst, Pfizer, Boehringer-Ingelheim, uniQure, Humana, Sun Life, and Envolve Pharmacy Solutions, outside the submitted work. Dr Yeung received a contract from ICER to be an evidence author for COVID-19 outpatient treatments.
贝因菲尔德女士、纳恩博士、惠廷顿博士、穆罕默德博士、皮尔逊博士报告在研究期间获得了阿诺德基金会、凯撒基金会健康计划公司、帕特里克和凯瑟琳·韦尔登·多纳休医学研究基金会、马萨诸塞州蓝十字蓝盾、英联邦基金会的资助；以及来自美国健康保险计划、安森、艾伯维、Alnylam、阿斯利康、百健、加州蓝盾、坎比亚健康服务公司、CVS、Editas、快捷药方、基因泰克/罗氏、葛兰素史克、哈佛朝圣者、医疗保健服务公司、健康伙伴、强生（杨森）、凯撒永久、利奥制药、美纳里克斯、默克、诺华、国家制药理事会、Premera、Prime 治疗学、Regeneron、赛诺菲、联合健康、HealthFirst、辉瑞、勃林格殷格翰、uniQure、信诺、太阳生活和 Envolve 药房解决方案的其他资助，这些资助均与提交的工作无关。杨博士收到了 ICER 的一份合同，成为 COVID-19 门诊治疗的证据作者。
Zotero 插件